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AbstrACt 
Objective The aim of this study was to assess the 
nutritional status of patients presenting with small bowel 
obstruction (SBO), along with associated nutritional 
interventions and clinical outcomes.
Design Prospective cohort study.
setting 131 UK hospitals with acute surgical services.
Participants 2069 adult patients with a diagnosis of SBO 
were included in this study. The mean age was 67.0 years 
and 54.7% were female.
Primary and secondary outcome measures Primary 
outcome was in-hospital mortality. Secondary outcomes 
recorded included: major complications (composite of in-
hospital mortality, reoperation, unplanned intensive care 
admission and 30-day readmission), complications arising 
from surgery (anastomotic leak, wound dehiscence), 
infection (pneumonia, surgical site infection, intra-
abdominal infection, urinary tract infection, venous 
catheter infection), cardiac complications, venous 
thromboembolism and delirium.
results Postoperative adhesions were the most 
common cause of SBO (49.1%). Early surgery (<24 hours 
postadmission) took place in 30.0% of patients, 22.0% 
underwent delayed operation and 47.9% were managed 
non-operatively. Malnutrition as stratified by Nutritional 
Risk Index was common, with 35.7% at moderate risk 
and 5.7% at severe risk of malnutrition. Dietitian review 
occurred in just 36.4% and 55.9% of the moderate and 
severe risk groups. In the low risk group, 30.3% received 
nutritional intervention compared with 40.7% in moderate 
risk group and 62.7% in severe risk group. In comparison 
to the low risk group, patients who were at severe or 
moderate risk of malnutrition had 4.2 and 2.4 times higher 
unadjusted risk of in-hospital mortality, respectively. 
Propensity-matched analysis found no difference in 
outcomes based on use or timing of parenteral nutrition.
Conclusions Malnutrition on admission is associated 
with worse outcomes in patients with SBO, and marked 
variation in management of malnutrition was observed. 
Future trials should focus on identifying effective and cost-
effective nutritional interventions in SBO.
bACkgrOunD
Small bowel obstruction (SBO) is a signifi-
cant health burden. There are approximately 
17 500 admissions to English hospitals and 
upwards of 300 000 admissions to US hospi-
tals each year,1–4 and is associated with high 
levels of morbidity and mortality.5 Patients 
with SBO may also be considered to have 
acute intestinal failure, which is defined by 
the European Society of Coloproctology as 
‘the reduction of gut function below the minimum 
necessary for the absorption of macronutrients and/
or fluid and electrolytes, such that intravenous 
supplementation is required to maintain health 
and/or growth’.6 Depending on the cause of 
the obstruction, patients may be managed 
strengths and limitations of this study
 ► This national prospective cohort study focusses on 
contemporary management of patients admitted to 
secondary care with acute small bowel obstruction, 
demonstrates high rates of malnutrition in this pa-
tient population and highlights wide variation in use 
of nutritional interventions.
 ► Rigorous data validation ensures high-quality assur-
ance for the data presented.
 ► The data presented is observational in nature, so 
only association can be assessed.
 ► Nutritional status is inferred from data collected at 
baseline and does not necessarily reflect dynamic 
changes or ongoing reassessment during hospital 
admission.
 ► Malnutrition has been assessed using two methods: 
with clinical judgement for most participants during 
data collection phase, and then using a post  hoc 
Nutritional Risk Index during analysis to allow robust 
assessment and comparisons.
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non-operatively until obstruction resolves spontaneously, 
or operatively where intestinal ischaemia is suspected 
or spontaneous resolution is deemed unlikely. Patients 
undergoing a period of non-operative management may 
be nil by mouth for several days and patients who have 
operative management will sustain varying degrees of 
postoperative ileus. These approaches, in the context 
of SBO, give rise to a prolonged period without enteral 
nutrition in a group of patients who are already known to 
be at high risk of malnutrition.7 
There is no specific guidance on the management 
of nutrition in SBO. Practice varies widely from early 
use of parenteral support to delayed use of nutritional 
interventions and current recommendations are based 
on low-quality evidence.6 8 9 Malnutrition is associated 
with poor outcomes10 11 in patients with acute illness 
and undergoing emergency surgery,10 which may be 
compounded by acute intestinal failure precipitated by 
SBO. It is therefore important to identify effective strat-
egies and future areas for research to improve the nutri-
tional management of patients with SBO.
The aim of this study was to describe the prevalence and 
variation of malnutrition, management and outcomes of 
patients with SBO.
MethODs
This national audit was conducted according to a prepub-
lished, predefined protocol,12 and is reported in line 
with the STrengthening the Reporting of OBservational 
studies in Epidemiology and Statistical Analyses and 
Methods in the Published Literature guidelines.13 14
As this study was a registered national audit, using 
routinely collected anonymised data, formal research 
ethics approval was not required with confirmation by 
the South-East Scotland Research and Ethics committee 
(reference: NR/1610AB10). All sites secured local audit 
and Caldicott Guardian permissions to participate and 
were not permitted to collect data without approvals 
in place. The audit was registered with the Healthcare 
Quality Improvement Partnership (http://www. hqip. org. 
uk).
Participants
All UK hospitals undertaking emergency general surgery 
were eligible for participation in this study. Adults aged 
18 years or over, admitted for suspected SBO were iden-
tified across an 8-week period from 16 January 2017 to 
13 March 2017 and followed up for 30 days following 
discharge. A diagnosis of SBO had to be made or 
confirmed by a consultant or a specialty trainee with 3 
or more years postgraduate surgical experience. Patients 
subsequently found to have non-mechanical SBO, left 
colonic obstruction causing SBO or who were managed 
with palliative intent from admission were excluded from 
this analysis.
Collaborative network
The National Audit of Small Bowel Obstruction was 
designed and delivered by trainee research collabora-
tives,15 with support from Royal Colleges, professional 
specialty associations and the Bowel Disease Research 
Foundation. Each site included oversight by a designated 
consultant surgeon, with data collection undertaken by 
trainee surgeons or allied health professionals. Roles of 
collaborators are presented in supplementary appendix 
A.
Data, definitions and validation
Data on route of referral to surgical team, baseline 
demographics (age, sex, height, weight), comorbidity 
(Charlson Comorbidity Index),16 admission biochem-
ical parameters (presence of acute kidney injury, white 
cell count (WCC), serum albumin) were captured. The 
period spent nil by mouth prior to referral, and dura-
tion of any preceding hospital stay (eg, on medical ward 
prior to referral) was documented. Use and timing of 
abdominal radiography, CT scanning and administration 
of water-soluble contrast agents was recorded. Data on 
operative interventions included timing, approach and 
key components of the operation were captured. Nutri-
tional data including body mass index, interval between 
last enteral intake and re-introduction of enteral nutri-
tion and use of nutritional support interventions were 
recorded. Nutritional Risk Index (NRI) was calculated 
using ideal body weight, current body weight and admis-
sion albumin.17 Patients were classified in three groups 
according to NRI group. The three groups were defined 
as ‘low risk’ (NRI>97.5), ‘moderate risk’ (NRI 83.5–97.5) 
and ‘severe risk’ (NRI<83.5).17
Data were entered onto a secure REDCap database18 
housed at the University of Sheffield. Records were pseu-
do-anonymised and only accessible to the local team and 
research team database administrators.
To ensure data accuracy, validation of key fields of 25% 
of all patient records was undertaken by an indepen-
dent investigator at each site who had not been involved 
in primary data collection. Records were identified for 
sampling by using a random number generator at the 
coordinating site and validation completed within a 
predetermined 30-day time window. Categorical fields 
were deemed accurate when there was exact agreement 
between responses. Continuous variables were consid-
ered accurate with a perfect match, or <0.5 rounding 
error of reported value. Unit data were excluded if the 
validation process was incomplete. Data accuracy was 
defined as number of accurate fields per patient divided 
by total number of fields per patient.
Public and patient involvement
This study was conceived following a public and patient 
research priority setting by the Association of Coloproc-
tology of Great Britain and Ireland.19 Throughout the 
study, a patient representative provided feedback and 
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input on study design, attended all steering group meet-
ings, and advised on interpretation of findings.
Outcomes
The primary outcome was time to in-hospital mortality 
(survival). Secondary outcomes recorded included: 
major complications (in-hospital mortality, reoperation, 
unplanned intensive care admission and 30-day readmis-
sion), complications arising from surgery (anastomotic 
leak, wound dehiscence), infection (pneumonia, surgical 
site infection, intra-abdominal infection, urinary tract 
infection, venous catheter infection), cardiac compli-
cations, venous thromboembolism and delirium. Case 
report forms and outcome definitions are available in 
supplementary appendix A and B, respectively.
statistical analysis
Data were summarised using simple descriptive statistics 
including count and percentages for categorical variables. 
Continuous variables were described using the mean 
average for central tendency, alongside the corresponding 
SD. For non-parametric continuous data, median average 
and corresponding IQR were used. To test for differences 
in baseline characteristics and outcomes across nutri-
tional risk groups, we used Χ2 test for categorical variables 
and Kruskal-Wallis or Student’s t-test/Wilcoxon rank sum 
test for continuous variables where appropriate.
Cox proportional hazards models were used to adjust 
for explanatory variables at the patient level and hospital 
level effects (entered as a cluster term) when assessing 
in-hospital survival. Effects estimates for this survival 
analysis are presented as HRs, with corresponding 
95% CIs. To consider the effects of other explanatory 
variables on binary outcomes, we constructed multilevel 
logistic regression models to generate effect estimates 
for each outcome of interest. There were two levels in 
these models, fixed effects at the patient level which 
adjusted for individual patient characteristics and centre 
level effects were considered as random effects. Effect 
estimates are presented as ORs, alongside their corre-
sponding 95% CIs. For both the adjusted survival anal-
ysis and multilevel logistic regression, the patient level 
explanatory variables were entered into the model on 
the basis of clinical plausibility and model selection was 
guided by the Akaike information criterion. All first-order 
and second-order interactions were examined. A sample 
of the population over 8 weeks was planned. Using data 
from a 2-week pilot in eight hospitals, it was anticipated 
that 80 hospitals would generate a sample size of 2000 
patients, which would be able to detect a difference in 
the primary outcome from 5% to 10%, where β=0.99 and 
α=0.05, with an allocation ratio of 1:3 across nutritional 
risk groups (low, moderate and severe).
To investigate the effects of parental nutrition (PN)/
total parental nutrition on outcomes in patients with 
SBO, we used a doubly-robust propensity score adjust-
ment to reduce the effects of selection bias. PN use is 
more common in unwell patients and previous studies 
have shown PN use to be associated with lower survival. 
To assess the effects of PN versus comparable controls, 
the analysis was limited to patients with adhesive SBO. 
As a sensitivity analysis, we then compared the effects of 
early PN (defined as <3 days after admission) and late 
PN (>3 days after admission) use. For both analyses, a 
doubly robust propensity score analysis was used. This 
differs from usual logistic regression modelling in that 
it estimates the relationship between a (non-randomly 
allocated) treatment and an outcome by jointly model-
ling a) the characteristics of patients that get the inter-
vention and b) the characteristics that increase the risk of 
outcome. Doubly robust methods fit a) and b) as simul-
taneous estimation equations (in this case using logistic 
regression) before estimating the link between the inter-
vention (PN) and outcome (death).
Finally, to compare variation across the UK in the nutri-
tional management of SBO, funnel plots were prepared 
to identify outliers and variation in clinical practice. The 
numerator was the proportion of participants receiving 
the intervention at a site, divided by the total number of 
cases at a site (presented on the X axis). Mean rate of 
intervention and CIs were calculated and plotted.
An exploratory analysis of the relationship between 
WCC at admission, albumin at admission and NRI was 
undertaken to assess for performance in the emergency 
setting, using Kruskal-Wallis test.
For all hypothesis tests, the threshold for statistical 
significance was set at the level p≤0.05. All analyses 
were performed in R V.3.4.4 (R Foundation for Statis-
tical Programming, Vienna, Austria) using the tidyverse, 
maggitr, ggplot2, lme4, MatchIt and finalfit packages.
results
A total of 2604 patients from 131 hospitals were 
entered into the study. Collaborators excluded 152 
patients following diagnostic test results that met the 
study exclusion criteria. As this analysis focusses on 
outcomes following treatment with curative intent, data 
on 73 patients who received end-of-life care have been 
excluded. Prior to statistical analysis, 18 patients were 
excluded as they did not meet the study inclusion criteria, 
and a further 292 patients were excluded due to missing 
baseline nutrition data, leaving a total of 2069 patients 
included in the final analysis (figure 1). The independent 
validation study confirmed data accuracy at 92%. Missing 
data were uncommon as demonstrated in table 1.
Patient characteristics
In this cohort, 30.0% of patients (622/2069) underwent 
surgery for SBO following a decision to operate within 
24 hours of admission, 22.0% (456/2069) received an 
operation after an initial trial of non-operative manage-
ment and 47.9% (991/2069) were managed non-oper-
atively (table 1). Across all patients, the mean average 
age was 67.0 years (SD=16.8), a small majority of patients 
were female (54.7%, 1131/2069) and postoperative 
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adhesions were the most common cause of SBO (49.1%, 
1016/2069) (online supplementary table S1). Malnu-
trition was common when stratified by NRI, with 35.7% 
at moderate risk (738/2069), 5.7% at severe risk 
(118/2069) and 58.6% (1213/2069) at low risk of malnu-
trition. Patient comorbidities were comparable across 
NRI groups: those in the low risk NRI group had 3 
Charlson Comorbidity Index points, compared with 4.2 
and 3.7 points in the moderate and severe risk groups, 
respectively. Online supplementary table S2 describes 
the procedures undergone by the operative and delayed 
operative groups.
Performance of nrI in detecting malnutrition
The effect of inflammation on the behaviour of NRI was 
explored. There was overlap of mean and SD of serum 
albumin according to WCC (figure 2), and for NRI by 
WCC category (figure 3). There were statistically signif-
icant differences in the means of the groups, although 
these are not clinically meaningful; the mean serum 
albumin varied from 38.9 to 39.8 g/L according to white 
cell count category (p=0.03), and the mean NRI score 
varied from 100.7 to 102.4 (p=0.02). There was variation 
in the rate of use of clinical tools to assess malnutrition. 
As inflammatory parameters (WCC, C reactive protein) 
did not correlate with a clinically important change in 
NRI (see plots in supplementary figure S1), the NRI has 
been used to facilitate comparisons in treatment.
rates of malnutrition and detection methods
A total of 81.6% (1688/2069) patients were assessed for 
malnutrition, either using clinical judgement or a formal 
screening tool (eg, Malnutrition Universal Screening 
Tool), and 32.8% (670/2069) were judged to be 
malnourished by their clinical team (table 2). In patients 
undergoing surgery, 84.6% (910/1076) were assessed 
for malnutrition compared with 78.6% (778/990) in the 
non-operative group. For patients whom the NRI iden-
tified as having a moderate risk of malnutrition, 36.4% 
(269/738) were reviewed by a dietician, with the average 
time to review taking 6.4 days (SD=6.5). For those at 
severe risk, this was slightly higher, with 55.9% reviewed 
by a dietician, with average time to review taking 4.5 
days (SD=5.0). Patients in the low risk group had fewer 
reviews, with an average time around 1 week. There was 
substantial variation in practice in the adjusted rates of 
dietician review across the UK (figure 4).
supportive nutritional interventions
Use of nutritional interventions varied across NRI groups. 
In the low risk group, 30.3% of patients received a nutri-
tional intervention (oral supplements, nasogastric (NG) 
or nasojejunal (NJ) feeding, or PN) compared with 40.7% 
in the moderate risk group and 62.7% in the severe risk 
group. The severe and moderate risk groups had higher 
rates of nutritional intervention and shorter times to 
instituting these (table 2). Adjusted rates of PN use varied 
widely, with some centres using PN widely and many 
others where patients did not receive any (figures 4-7).
Malnutrition and outcomes
Patients who were at a severe or moderate risk of malnu-
trition had 4.2 and 2.4 times higher unadjusted risk, 
respectively, of in-hospital mortality versus those in 
the low risk group (table 3). Patients in the severe or 
moderate risk groups were also more likely to develop 
infections, delirium and experience and poor surgical 
outcomes including re-operation. When demographic 
and hospital variables were adjusted for in the Cox regres-
sion model, the survival of patients in comparison to the 
low risk group was significant worse for both the high risk 
(HR 2.18, 95% CI 1.14 to 4.17, p=0.018) and moderate 
risk (HR 1.55, 95% CI 1.01 to 2.40, p=0.046) patients 
(table 4). For patients in the severe risk group, those 
who underwent surgery had a significantly lower adjusted 
hazard for mortality than those managed non-operatively 
(immediate operation HR 0.08, 95% CI 0.01 to 0.96, 
p=0.047; delayed operation HR 0.30, 95% CI 0.08 to 1.13, 
p=0.076). The same was found when the moderate and 
severe groups were combined (immediate operation HR 
0.43, 95% CI 0.26 to 0.73, p=0.002; delayed operation HR 
0.41, 95% CI 0.25 to 0.68, p<0.001).
Across all three NRI groups, the time to resumption of 
enteral intake was around 1 week (table 3). When adjusted 
for confounding factors, NRI risk group was not associ-
ated with delayed time to resumption of enteral intake 
(online supplementary table S3). Operative manage-
ment was associated with a delay in resumption of enteral 
intake when compared with non-operative management 
(immediate operation HR 0.79, 95% CI 0.68 to 0.92, 
Figure 1 Patient inclusion flow chart.
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Table 1 Patient characteristics
Low
risk (n=1212)
Moderate risk
(n=738)
Severe risk
(n=118) P value
Age (years)
  Mean (SD) 65 (16.9) 70.3 (16.2) 67 (16.7) <0.001*
Sex
  Male 546 (45.0) 335 (45.4) 56 (47.5) 0.916
  Female 666 (54.9) 403 (54.6) 62 (52.5)
  Missing 1 (0.1) 0 (0.0) 0 (0.0)
Charlson Comorbidity Index
  Mean (SD) 3 (5.8) 4.2 (6.9) 3.7 (6.7) <0.001*
Admission albumin (g/dL)
  Mean (SD) 43.9 (4.2) 34.0 (3.0) 23.8 (4.0) <0.001*
Accommodation prior to admission
  Own home 1200 (98.9) 716 (97.0) 112 (94.9) 0.002
  Residential home 2 (0.2) 9 (1.2) 1 (0.8)
  Nursing home 10 (0.8) 13 (1.8) 5 (4.2)
  Missing 1 (0.1) 0 (0.0) 0 (0.0)
Source of referral
  Emergency department 860 (70.9) 469 (63.6) 70 (59.3) <0.001
  General practice 225 (18.5) 154 (20.9) 18 (15.3)
  Clinic admission 18 (1.5) 12 (1.6) 4 (3.4)
  Referral from inpatient team 110 (9.1) 103 (14.0) 26 (22.0)
AKI on admission
  No 974 (80.3) 559 (75.7) 81 (68.6) 0.012
  Yes 238 (19.6) 179 (24.3) 37 (31.4)
  Missing 1 (0.1) 0 (0.0) 0 (0.0)
Admission white cell count (/L)
  <11.9×109 676 (55.7) 427 (57.9) 76 (64.4) 0.165
  12.0–15.9×109 336 (27.7) 178 (24.1) 23 (19.5)
  >16.0×109 201 (16.6) 133 (18.0) 19 (16.1)
Radiology performed
  No imaging 12 (1.0) 12 (1.6) 1 (0.8) 0.295
  AXR only 232 (19.1) 118 (16.0) 20 (16.9)
  CT only 166 (13.7) 108 (14.6) 23 (19.5)
  CT and AXR 803 (66.2) 500 (67.8) 74 (62.7)
Final treatment group
  Non-operative 604 (49.8) 327 (44.3) 60 (50.8) 0.071
  Immediate operation 339 (27.9) 246 (33.3) 37 (31.4)
  Delayed operation 270 (22.3) 165 (22.4) 21 (17.8)
Aetiology
  Adhesions 673 (55.5) 300 (40.7) 43 (36.4) <0.001
  Crohn’s disease 51 (4.2) 29 (3.9) 7 (5.9)
  Hernia 208 (17.1) 135 (18.3) 14 (11.9)
  Malignancy 58 (4.8) 80 (10.8) 19 (16.1)
  Other 147 (12.1) 148 (20.1) 30 (25.4)
  Missing 76 (6.3) 46 (6.2) 5 (4.2)
Continued
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p=0.003; delayed operation NRI HR 0.52, 95% CI 0.46 to 
0.58, p<0.001).
Propensity-matched analysis for Pn use
Two analyses were performed, one for use of PN and the 
other for use and timing of PN. Propensity score matching 
produced balanced treatment groups for both analyses, 
with few significant differences (online supplementary 
table S4 and S5). The difference between groups for the 
use of PN was in the Charlson Comorbidity Index, where 
a higher score was associated with increased use. Patients 
who required critical care (HDU/ICU) support were 
more likely to receive PN, therefore this was included 
in the matching algorithm. Following propensity score 
matching and adjustment via a doubly robust approach, 
PN use was not significantly associated with worse 
survival (adjusted HR 0.63, 95% CI 0.25 to 1.57, p=0.319, 
online supplementary table S6) and there appeared to be 
little difference between early and late PN use (adjusted 
early HR 0.51, 95% CI 0.11 to 2.42, p=0.397; adjusted late 
HR 0.68, 95% CI 0.25 to 1.85, p=0.448, online supplemen-
tary table S7). Notably, the group receiving early PN were 
more likely to have undergone immediate surgery, rather 
than delayed surgery or non-operative management.
DIsCussIOn
This study identified that one-third of patients with acute 
SBO are at risk of malnutrition, and that malnutrition 
risk is significantly associated with poorer outcomes. 
There is wide variation in use of supportive enteral and 
parenteral nutrition strategies. Where it occurred, dieti-
tian assessment of this group occurred on average 1 week 
after admission.
The proportion of cases of SBO due to adhesions is 
lower in this cohort than the 74% reported in a cohort 
spanning 1985–1996, whereas causes such as malignancy 
are more prevalent in this modern cohort.20 This change 
in underlying aetiology and the rates of malnutrition 
associated with malignancy and increasingly prevalent 
Low
risk (n=1212)
Moderate risk
(n=738)
Severe risk
(n=118) P value
Operative approach
  Laparoscopic 53 (4.4) 30 (4.1) 5 (4.2) 0.186
  Laparoscopic converted to open 43 (3.5) 29 (3.9) 0 (0.0)
  Open (groin) 42 (3.5) 39 (5.3) 2 (1.7)
  Open (midline) 434 (35.8) 283 (38.3) 45 (38.1)
  Open (other) 34 (2.8) 22 (3.0) 3 (2.5)
  N/A 607 (50.0) 335 (45.4) 63 (53.4)
Small bowel resection
  No small bowel resection 446 (36.8) 292 (39.6) 40 (33.9) 0.225
  Small bowel resection 158 (13.0) 112 (15.2) 16 (13.6)
  N/A 609 (50.2) 334 (45.3) 62 (52.5)
Stratified by NRI categories across columns.
Values are N (%) unless otherwise specified. 
Tests are Χ2, unless otherwise indicated by asterisk (*), where they are Kruskal-Wallis. Albumin not tested as this comprises part of NRI.
AKI, acute kidney injury; AXR, plain-film abdominal X-ray; N/A not applicable; NRI, Nutritional Risk Index.
Table 1 Continued 
Figure 2 Relationship of admission white cell count to 
admission albumin.
Figure 3 Relationship of admission white cell count to 
Nutritional Risk Index.
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Table 2 Nutritional assessment and characteristics
Low risk (n=1213) Moderate risk (n=738) Severe risk (n=118) P value
Was the patient identified as malnourished at any point?
  No 868 (71.6) 459 (62.2) 52 (44.1) <0.001
  Yes 335 (27.6) 278 (37.7) 66 (55.9)
  Missing 10 (0.8) 1 (0.1) 0 (0.0)
Malnutrition risk assessment
  Assessed 980 (80.8) 605 (82.0) 103 (87.3) 0.345
  Not assessed 232 (19.1) 131 (17.8) 15 (12.7)
  Missing 1 (0.1) 2 (0.3) 0 (0.0)
Was the patient assessed using clinical judgement?
  No 342 (28.2) 206 (27.9) 26 (22.0) 0.292
  Yes 597 (49.2) 370 (50.1) 67 (56.8)
  Not assessed 273 (22.5) 158 (21.4) 25 (21.2)
  Missing 1 (0.1) 4 (0.5) 0 (0.0)
Was the patient assessed using a nutritional assessment tool?
  No 259 (21.4) 175 (23.7) 27 (22.9) 0.842
  Yes 785 (64.7) 467 (63.3) 78 (66.1)
  Not assessed 167 (13.8) 94 (12.7) 13 (11.0)
  Missing 2 (0.2) 2 (0.3) 0 (0.0)
Was the patient reviewed by a dietitian or nutrition team at any point during admission?
  No 909 (74.9) 466 (63.1) 52 (44.1) <0.001
  Yes 302 (24.9) 269 (36.4) 66 (55.9)
  Missing 2 (0.2) 3 (0.4) 0 (0.0)
Time to review by dietician (days)
  Mean (SD) 7.9 (22.4) 6.4 (6.5) 4.5 (5) 0.001
Nutritional intervention
  No 842 (69.4) 433 (58.7) 44 (37.3) <0.001
  Yes 368 (30.3) 300 (40.7) 74 (62.7)
  Missing 3 (0.2) 5 (0.7) 0 (0.0)
Were oral supplements (eg, fortisips) started at any point during admission?
  No 918 (75.7) 502 (68.0) 67 (56.8) <0.001
  Yes 290 (23.9) 231 (31.3) 51 (43.2)
  Missing 5 (0.4) 5 (0.7) 0 (0.0)
Time to oral supplements (days)
  Mean (SD) 7.6 (8) 8.3 (9.2) 8.6 (11.6) 0.961
Was NG or NJ feed started at any point during admission?
  No 1157 (95.4) 683 (92.5) 101 (85.6) <0.001
  Yes 53 (4.4) 52 (7.0) 17 (14.4)
  Missing 3 (0.2) 3 (0.4) 0 (0.0)
Time to NG/NJ feed (days)
  Mean (SD) 8.8 (9.1) 10.9 (14) 24.6 (58.5) 0.501
Was TPN started at any point during the admission?
  No 1064 (87.7) 612 (82.9) 84 (71.2) <0.001
  Yes 147 (12.1) 125 (16.9) 34 (28.8)
  Missing 2 (0.2) 1 (0.1) 0 (0.0)
Time to PN/TPN (days)
  Mean (SD) 6.5 (6.2) 6.6 (6.4) 4.3 (3.8) 0.030
Stratified by Nutritional Risk Index categories across columns.
Tests are Χ2, unless otherwise indicated by asterisk (*), where they are Kruskal-Wallis.
Values are N (%) unless otherwise specified. 
NG, nasogastric; NJ, nasojejunual; PN/TPN, parenteral nutrition/total parenteral nutrition.
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frailty mean that nutrition is an area which merits further 
attention. The National Institute for Health and Care 
Excellence (NICE) has provided guidelines addressing 
the identification and management of nutrition in 
surgical patients, which are applicable to this popula-
tion.8 Their recommendation is that all hospital patients 
should be screened for malnutrition on admission and 
weekly thereafter. In this study, only two-thirds of patients 
were identified as malnourished in this way. While this 
may highlight problems with the accuracy of nutritional 
assessment on admission, it should also be recognised 
that the nutritional state in patients with SBO is dynamic. 
Patients may be nutritionally replete when admitted to 
hospital, but later develop nutritional problems through 
intestinal failure, something which is more likely to be 
determined on clinical grounds sometime after admis-
sion. This may explain why 28% of patients in the low 
risk NRI group (calculated from admission data) were 
subsequently judged to have malnutrition and 12% of this 
group ended up receiving parenteral nutrition.
NICE guidance advocates use of oral nutritional supple-
ments in patients at risk of malnutrition, and parenteral 
nutrition in those without oral intake for 5 days or more. 
Adherence to this aspect of NICE guidance was not 
reflected in this study. Where patients were identified 
as being at risk, this did not trigger clinical actions in 
many cases. One possibility for this discrepancy may lie in 
delayed access to dietitian review. Outside of critical care 
units, dieticians are typically the gatekeepers for nutri-
tional interventions in UK services. Limited resource or 
capacity may be reflected by the low rates or absence of 
nutritional interventions such as NG/NJ feeding or PN in 
some units, suggesting ‘supply sensitive’ care,21 although 
poor awareness of the impact of malnutrition on patient 
outcomes and the evolving nature of malnutrition in SBO 
may also be major contributory factors.
The finding of high rates of malnutrition is common 
in patients with acute illnesses.10 11 The concern with 
SBO, however, is that malnutrition is not readily correct-
able through conventional enteral interventions due to 
compromise of intestinal function.6 This puts patients at 
risk of malnutrition through acute illness and prevents 
any improvement in nutritional status due to acute 
gastrointestinal failure. It is well recognised that attaining 
adequate caloric intake is difficult in this patient popu-
lation, largely due to disruption in enteral feeding and 
inability of a poorly functioning gastrointestinal tract to 
absorb sufficient nutrients.22 23 Malnutrition could be 
considered a potentially modifiable risk factor to reduce 
mortality and prevent complications if an appropriate 
route of feeding can be established to overcome these 
issues.
Trials in the elective setting addressing preoperative 
or perioperative nutritional interventions in elective 
cancer resection populations have shown benefit over 
Figure 4 Dietician review rates. Red bound is 99% CI and 
blue bound is 95% CI. Average set at the national average 
rate.
Figure 5 Use of oral supplements. Red bound is 99% 
CI and blue bound is 95% CI. Average set at the national 
average rate.
Figure 6 Use of nasogastric (NG)/nasojejunal (NJ) feed. Red 
bound is 99% CI and blue bound is 95% CI. Average set at 
the national average rate.
Figure 7 Parental nutrition (PN)/total parental nutrition (TPN) 
use rates. Red bound is 99% CI and blue bound is 95% CI. 
Average set at the national average rate.
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Table 3 Outcomes by nutritional state
Low risk (n=1213) Moderate risk (n=738) Severe risk (n=118) P value
In-hospital mortality
  No 1164 (96.0) 668 (90.5) 98 (83.1) <0.001
  Yes 46 (3.8) 69 (9.3) 19 (16.1)
  Missing 3 (0.2) 1 (0.1) 1 (0.8)
Time with no enteral intake
  <5 days 705 (58.1) 379 (51.4) 45 (38.1) <0.001
  >5 days 439 (36.2) 308 (41.7) 60 (50.8)
  Missing 69 (5.7) 51 (6.9) 13 (11.0)
Time to resumption of enteral intake
  Mean (SD) 7.2 (14.5) 7.8 (9.9) 8 (7.4) <0.001
Urinary tract infection
  No 1150 (94.8) 691 (93.6) 108 (91.5) 0.181
  Yes—not urinary catheter 
associated
40 (3.3) 29 (3.9) 4 (3.4)
  Yes—urinary catheter 
associated
20 (1.6) 14 (1.9) 6 (5.1)
  Missing 3 (0.2) 4 (0.5) 0 (0.0)
Lower respiratory tract infection
  No 1095 (90.3) 625 (84.7) 94 (79.7) <0.001
  Yes 115 (9.5) 112 (15.2) 24 (20.3)
  Missing 3 (0.2) 1 (0.1) 0 (0.0)
Deep surgical site infection
  No 1174 (96.8) 710 (96.2) 111 (94.1) 0.508
  Yes 37 (3.1) 26 (3.5) 7 (5.9)
  Missing 2 (0.2) 2 (0.3) 0 (0.0)
Superficial surgical site infection
  No 1138 (93.8) 690 (93.5) 107 (90.7) 0.645
  Yes 73 (6.0) 46 (6.2) 11 (9.3)
  Missing 2 (0.2) 2 (0.3) 0 (0.0)
Abdominal wall dehiscence
  No 1190 (98.1) 723 (98.0) 114 (96.6) 0.577
  Yes 18 (1.5) 12 (1.6) 4 (3.4)
  Missing 5 (0.4) 3 (0.4) 0 (0.0)
Anastomotic leak
  No 1204 (99.3) 726 (98.4) 116 (98.3) 0.330
  Yes 7 (0.6) 9 (1.2) 2 (1.7)
  Missing 2 (0.2) 3 (0.4) 0 (0.0)
Radiologically guided drainage 
  No 1196 (98.6) 725 (98.2) 111 (94.1) 0.002
  Yes 14 (1.2) 10 (1.4) 7 (5.9)
  Missing 3 (0.2) 3 (0.4) 0 (0.0)
Venous thromboembolism (PE or DVT)
  No 1200 (98.9) 724 (98.1) 113 (95.8) 0.016
  Yes 9 (0.7) 11 (1.5) 5 (4.2)
  Missing 4 (0.3) 3 (0.4) 0 (0.0)
Continued
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no intervention in terms of reduced hospital length of 
stay, improved hand grip strength and reduced compli-
cations.17 24 25 This effect was greatest in the most 
malnourished groups.17 Studies in critical care on the 
use of PN have not demonstrated significant survival 
benefit and modest improvements in quality of life or 
time on ventilator.26 27 However, when trial results are 
assessed according to outcome, it appears that PN may 
be associated with reduced rates of complications of 
care.28 The pilot TOP-UP trial has suggested a benefit 
to supplemental PN in the surgical population.29 These 
trials typically included comparison with enteral feeding 
in predominantly medical populations, who often have 
normal intestinal function and continuity. There are few 
studies addressing this question exclusively in the surgical 
population, and those targeted at the surgical population 
are generally of low quality and do not make clinically 
useful comparisons for SBO.30 While propensity-matched 
analyses in this study did not demonstrate any effect 
from the use of PN, it is important to consider that this 
represents a sample of the subgroup who received PN 
in the study, meaning there is a high degree of selection 
bias. The sample is also too small with heterogeneity of 
aetiology to demonstrate a modest but clinically plausible 
difference between the two groups that has been demon-
strated in other surgical studies.31
strengths and limitations
This is a large study of real-world practice from across the 
UK, and benefits from the support of trainee research 
collaboratives and low rates of missing data. These groups 
have demonstrated ability to access many clinical units as 
well deliver quality clinical data.15 It also provides novel 
data on nutritional management of a large cohort of 
patients with a common emergency surgical condition. 
These real-world data can be used to generate hypoth-
eses to guide further research based on patient-centred 
outcomes.
The limitations of this study are its observational nature, 
from which it is possible only to identify associations, not 
to determine causation. To examine outcomes, assess-
ment of malnutrition was based on NRI from admissions 
Low risk (n=1213) Moderate risk (n=738) Severe risk (n=118) P value
Delirium
  No 1172 (96.6) 690 (93.5) 102 (86.4) <0.001
  Yes 38 (3.1) 46 (6.2) 16 (13.6)
  Missing 3 (0.2) 2 (0.3) 0 (0.0)
Cardiovascular event (MI, new heart block, stroke, TIA) 
  No 1146 (94.5) 679 (92.0) 108 (91.5) 0.168
  Yes 64 (5.3) 55 (7.5) 10 (8.5)
  Missing 3 (0.2) 4 (0.5) 0 (0.0)
Reoperation
  No 582 (48.0) 380 (51.5) 52 (44.1) 0.027
  Yes 25 (2.1) 27 (3.7) 6 (5.1)
  Missing 606 (50.0) 331 (44.9) 60 (50.8)
Unplanned HDU/ICU admission
  No 1111 (91.6) 644 (87.3) 94 (79.7) <0.001
  Yes— intensive care unit 50 (4.1) 53 (7.2) 17 (14.4)
  Yes—high dependency 
care
44 (3.6) 36 (4.9) 7 (5.9)
  Missing 8 (0.7) 5 (0.7) 0 (0.0)
Readmission within 30 days
  No 1029 (84.8) 599 (81.2) 90 (76.3) 0.010
  Yes 164 (13.5) 112 (15.2) 23 (19.5)
  Missing 20 (1.6) 27 (3.7) 5 (4.2)
Length of stay (days)
  Mean (SD) 10 (12.4) 13.3 (13.6) 17.8 (14.4) <0.001
Stratified by Nutritional Risk Index categories across columns.
Values are N (%) unless otherwise specified. Tests are Χ2, unless otherwise indicated by asterisk (*), where they are Kruskal-Wallis.
DVT, deep vein thrombosis; HDU, high dependency unit (level 2); ICU, intensive care unit/intensive therapy unit (level 2/3); MI, myocardial 
infarction; PE, pulmonary embolism; TIA, transient ischaemic attack.
Table 3 Continued 
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data and does not capture the dynamic aspect of repeated 
clinical assessments. NRI is also partly dependent on 
serum albumin level, which is rarely considered to be a 
marker of nutritional status per se. Nevertheless, hypoal-
buminaemia is likely to result from sepsis and therefore 
to be associated with a catabolic state. It is recognised that 
Table 4 Model for survival (mortality)
HR (univariable) HR (multivariable)
Nutritional Risk Index
  Low risk – – 
  Moderate risk 1.81 (1.24–2.65, p=0.002) 1.55 (1.01–2.40, p=0.046)
  Severe risk 2.26 (1.29–3.96, p=0.004) 2.18 (1.14–4.17, p=0.018)
Final treatment group
  Non-operative – – 
  Immediate operation 0.57 (0.38–0.85, p=0.005) 0.52 (0.34–0.80, p=0.003)
  Delayed operation 0.33 (0.21–0.53, p<0.001) 0.35 (0.22–0.57, p<0.001)
Age at admission to study (years)
  Mean (SD) 1.05 (1.03–1.07, p<0.001) 1.05 (1.03–1.06, p<0.001)
Sex
  Male – – 
  Female 1.00 (0.70–1.41, p=0.993) 1.09 (0.73–1.63, p=0.668)
Charlson Comorbidity Index
  Mean (SD) 1.05 (1.03–1.07, p<0.001) 1.01 (0.99–1.04, p=0.336)
Admission white cell count
  <11.9×109 – – 
  12.0–15.9×109 1.00 (0.64–1.55, p=0.995) 1.10 (0.67–1.81, p=0.698)
  >16.0×109 1.75 (1.16–2.65, p=0.008) 1.66 (1.02–2.70, p=0.040)
Aetiology
  Adhesions – – 
  Crohn’s disease 0.21 (0.03–1.55, p=0.127) 0.46 (0.06–3.46, p=0.452)
  Hernia 2.04 (1.30–3.21, p=0.002) 2.02 (1.24–3.30, p=0.005)
  Malignancy 2.32 (1.41–3.82, p=0.001) 2.57 (1.49–4.44, p=0.001)
  Other 0.95 (0.55–1.65, p=0.857) 1.00 (0.59–1.69, p=0.991)
Was PN/TPN started at any point during the admission?
  No – – 
  Yes 0.74 (0.49–1.11, p=0.148) 1.33 (0.83–2.15, p=0.237)
AKI on admission
  No – – 
  Yes 1.67 (1.17–2.39, p=0.005) 1.39 (0.91–2.13, p=0.123)
  Yes 1.67 (1.17–2.39, p=0.005) 1.39 (0.91–2.13, p=0.123)
Initial management strategy
  Non-operative – – 
  Operative (decision made within 
24 hours of admission)
0.91 (0.63–1.32, p=0.615) – 
Source of referral
  Emergency department – – 
  General practice 0.86 (0.54–1.38, p=0.533) – 
  Clinic admission 0.00 (0.00–Infinity, p=0.993) – 
  Referral from inpatient team 1.04 (0.66–1.62, p=0.877) – 
AKI, acute kidney injury; PN, parental nutrition; TPN, total parental nutrition.
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duration of symptoms prior to admission correlates with 
worse outcomes.32 This was not directly measured in this 
study, rather duration of time without enteral nutrition 
prior to admission. The level of agreement between these 
two measures is not known.
explanations for findings
NICE advocates nutritional interventions wherever 
malnutrition is identified, with the mode of delivery 
defined by disease state and time factors (eg, PN to be 
withheld unless period of starvation is likely to exceed 
5 days).8 The most recent European Society for Clin-
ical Nutrition and Metabolism guidelines do not offer 
a specific timeframe for commencement of nutritional 
support, although recommend early support.9 The Amer-
ican Society for Parenteral and Enteral Nutrition guide-
lines suggest nutritional interventions are withheld for a 
few days postoperatively, except where there is evidence 
of hypermetabolism or critical malnutrition.33 Each of 
these guidelines has a focus on nutrition in the elective 
surgical setting, where most of the evidence is found. 
The variation in recommendations from these respected 
bodies suggests that the underlying evidence base is not 
adequate to guide highly prescriptive treatment decisions 
on surgical patients in the emergency setting and partic-
ularly where the underlying pathology precipitates acute 
intestinal failure. This is likely to be reflected in the varia-
tion in practice identified in this study.21
Implications for policy makers
This study shows there is wide variation in the nutri-
tional management of patients with SBO. Recent initia-
tives such as the National Emergency Laparotomy 
Audit have reduced variation in emergency practice.1 
Policy makers should include nutritional management 
in routine reports of emergency surgical practice. Clin-
ical sites should review local practices to reduce factors 
associated with variation in their unit, such as recording 
of malnutrition risk, access to dietitians and nutritional 
support teams. Research has not yet assessed the role of 
nutritional interventions, for example, early parenteral 
nutrition in patients with SBO30 and research in this area 
merits funding opportunities. Investment in hospital 
nutrition and dietetic services must accompany this.
Data from this study show that over half of patients with 
SBO are nil by mouth for >5 days during their hospital 
stay. Patients admitted to hospital in a poor nutritional 
state are therefore at heightened risk of developing 
profound malnutrition during admission. Arguably, 
these patients perhaps should be established on paren-
teral nutrition from admission, while nutritionally replete 
patients should receive nutrition within 5–7 days of being 
nil by mouth. This would be in line with NICE guidelines, 
and the role of PN being suggested by pilot data from 
the TOP-UP trial.29 Most importantly, a thorough assess-
ment of nutritional status is required on admission, which 
should also establish how many days patients have gone 
without oral nutrition prior to being in hospital. This 
length of time should be factored into any recommenda-
tions for nutritional support.
Implications for future research
Funding bodies including the National Institute for 
Health Research and Medical Research Council have iden-
tified nutrition research as a key area for further research. 
Given the highlighted deficiencies in the evidence base 
and the variation seen here, a commissioned funding call 
may help identify optimum nutritional strategies in SBO.
COnClusIOn
Malnutrition is prevalent among the SBO population and 
is associated with poor outcomes. There is broad recog-
nition of malnutrition in this setting, but variation in the 
use of nutritional interventions. This national audit has 
helped develop hypotheses that require testing in future 
research to improve outcomes for patients with SBO.
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